Main Industry
Health Care
Main Product/Service
1. ASP5006
2. ASP4755
2. ASP4755
Founded Year
2011
Unified Business No.
53203779
Status
Closed
Number of Employees
8
Total Paid-in
Capital
151,400,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Asclepiumm Taiwan Co., Ltd. was established in 2011 and is a pioneering pharmaceutical development company focused on addressing unmet medical needs in the market. The company specializes in the research and development of innovative first-in-class drugs utilizing the ASC fusion protein platform and unique peptide drug development. In 2016, Asclepiumm established three major research axes: peptides, antibodies, and fusion proteins.
As of 2023, the company has developed two series of peptide drugs, an antibody platform, and a fusion protein drug platform, all of which have been granted patents in the United States, China, and Japan. These research achievements will be further developed through collaborations with professional Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) in the subsequent phases of drug development.
The products under development are characterized by their novelty, addressing urgent medical needs, and the potential to become blockbuster drugs with annual sales exceeding 1 billion USD. There are opportunities for early-stage licensing and collaboration with international pharmaceutical giants, which can accelerate and enhance the success of new drug development and contribute to the expansion of future markets.
As of 2023, the company has developed two series of peptide drugs, an antibody platform, and a fusion protein drug platform, all of which have been granted patents in the United States, China, and Japan. These research achievements will be further developed through collaborations with professional Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) in the subsequent phases of drug development.
The products under development are characterized by their novelty, addressing urgent medical needs, and the potential to become blockbuster drugs with annual sales exceeding 1 billion USD. There are opportunities for early-stage licensing and collaboration with international pharmaceutical giants, which can accelerate and enhance the success of new drug development and contribute to the expansion of future markets.
